Dysfunctional Vascular Endothelium as a Driver of Atherosclerosis: Emerging Insights Into Pathogenesis and Treatment
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Atherosclerosis, the chronic accumulation of cholesterol-rich plaque within arteries, is associated with a broad spectrum of cardiovascular diseases including myocardial infarction, aortic aneurysm, peripheral vascular disease, and stroke. Atherosclerotic cardiovascular disease remains a leading cause of mortality in high-income countries and recent years have witnessed a notable increase in prevalence within low- and middle-income regions of the world. Considering this prominent and evolving global burden, there is a need to identify the cellular mechanisms that underlie the pathogenesis of atherosclerosis to discover novel therapeutic targets for preventing or mitigating its clinical sequelae. Despite decades of research, we still do not fully understand the complex cell-cell interactions that drive atherosclerosis, but new investigative approaches are rapidly shedding light on these essential mechanisms. The vascular endothelium resides at the interface of systemic circulation and the underlying vessel wall and plays an essential role in governing pathophysiological processes during atherogenesis. In this review, we present emerging evidence that implicates the activated endothelium as a driver of atherosclerosis by directing site-specificity of plaque formation and by promoting plaque development through intracellular processes, which regulate endothelial cell proliferation and turnover, metabolism, permeability, and plasticity. Moreover, we highlight novel mechanisms of intercellular communication by which endothelial cells modulate the activity of key vascular cell populations involved in atherogenesis, and discuss how endothelial cells contribute to resolution biology – a process that is dysregulated in advanced plaques. Finally, we describe important future directions for preclinical atherosclerosis research, including epigenetic and targeted therapies, to limit the progression of atherosclerosis in at-risk or affected patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026 · cited 2×
“Promoting Inflammation Resolution to Mitigate Atherosclerosis The NLRP3 inflammasome is now recognized as a key player in the coordination of vascular inflammation and onset of atherogenesis (Duewell et al., 2010; Jin and Fu, 2019).”
BackgroundThe changing landscape of atherosclerosis
Libby, P. (2021) · Nature · doi:10.1038/s41586-021-03392-8 · Cited by 2,873 · cited 4×
“Progressive thinning of the fibrous cap results from an inflammation-associated decrease in collagen synthesis and increase in degradation, which in combination with erosion of the endothelium, contributes to plaque rupture, thrombosis, and obstruction of the affected vessel (Libby, 2021).”
BackgroundInfluentialMechanisms of plaque formation and rupture
Bentzon, J. F., Otsuka, F., Virmani, R., & Falk, E. (2014) · Circulation Research · doi:10.1161/circresaha.114.302721 · Cited by 2,391
Vascular smooth muscle cells in atherosclerosis
Bennett, M. R., Sinha, S., & Owens, G. K. (2016) · Circulation Research · doi:10.1161/circresaha.115.306361 · Cited by 2,179 · cited 1×
“Vascular SMCs that comprise the medial layer of arteries migrate to the intima, form fibrous tissue through the production of collagen and elastin, and can also differentiate into macrophage-like foam cells in the developing plaque (Bennett et al., 2016).”
BackgroundCellular Fatty Acid Metabolism and Cancer
Currie, E., Schulze, A., Zechner, R., Walther, T. C., & Farese, R. V. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.017 · Cited by 2,123 · cited 1×
“Fatty acid oxidation, used as a secondary source of energy by ECs, is modulated by carnitine palmitoyltransferase 1A-mediated shuttling of fatty acids to the mitochondria and ATP production via adenosine monophosphate activated protein kinase signaling (Dagher et al., 2001; Currie et al., 2013).”
BackgroundRoles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis
Förstermann, U., Xia, N., & Li, H. (2017) · Circulation Research · doi:10.1161/circresaha.116.309326 · Cited by 1,519 · cited 1×
“In contrast to regions of laminar flow, altered hemodynamics in atheroprone regions has been associated with increased oxidative stress (Förstermann et al., 2017), reorganization of cytoskeletal and cell-cell junction proteins (Chong et al.”
BackgroundSilverman, M. G., Ference, B. A., Im, K., Wiviott, S. D., Giugliano, R. P., Grundy, S. M., Braunwald, E., & Sabatine, M. S. (2016) · JAMA · doi:10.1001/jama.2016.13985 · Cited by 1,483
Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
Bäck, M., Yurdagul, A., Tabas, I., Öörni, K., & Kovanen, P. T. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0169-2 · Cited by 1,341 · cited 1×
“The endothelium is an essential regulator of vascular homeostasis, defined as the balance of vascular injury and repair, and dynamic changes in endothelial phenotype can both potentiate and limit atherogenesis and associated complications (Bäck et al., 2019; Chen P.-Y. et al., 2020).”
BackgroundBlood Flow Regulation by S -Nitrosohemoglobin in the Physiological Oxygen Gradient
Stamler, J. S., Jia, L., Eu, J. P., McMahon, T. J., Demchenko, I. T., Bonaventura, J., Gernert, K., & Piantadosi, C. A. (1997) · Science · doi:10.1126/science.276.5321.2034 · Cited by 1,050
NF-κB: pivotal mediator or innocent bystander in atherogenesis?
Collins, T., & Cybulsky, M. I. (2001) · Journal of Clinical Investigation · doi:10.1172/jci10373 · Cited by 727 · cited 2×
“, 2004; Berk, 2008), which are induced by NF-κB in regions of disturbed flow (Hajra et al., 2000; Collins and Cybulsky, 2001).”
BackgroundCD47-blocking antibodies restore phagocytosis and prevent atherosclerosis
Kojima, Y., Volkmer, J.-P., McKenna, K., Civelek, M., Lusis, A. J., Miller, C. L., Direnzo, D., Nanda, V., Ye, J., Connolly, A. J., et al. (2016) · Nature · doi:10.1038/nature18935 · Cited by 683 · cited 1×
“, the clearing of apoptotic cells) is being established with preclinical studies, wherein atherosclerotic plaque progression has been attenuated by proefferocytic cluster of differentiation 47 (CD47)-blocking therapies (Kojima et al., 2016; Flores et al., 2020) or activation of the macrophage cell surface receptor MER…”
BackgroundVascular endothelium – Gatekeeper of vessel health
Cahill, P. A., & Redmond, E. M. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.03.007 · Cited by 518
Recent advances in arginine metabolism: roles and regulation of the arginases
Morris Jr, S. M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00278.x · Cited by 485
Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis
Wang, K.-C., Yeh, Y.-T., Nguyen, P., Limqueco, E., Lopez, J., Thorossian, S., Guan, K.-L., Li, Y.-S. J., & Chien, S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613121113 · Cited by 471
Aerobic glycolysis tunes YAP/TAZ transcriptional activity
Enzo, E., Santinon, G., Pocaterra, A., Aragona, M., Bresolin, S., Forcato, M., Grifoni, D., Pession, A., Zanconato, F., Guzzo, G., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490379 · Cited by 414 · cited 1×
“Importantly, YAP/TAZ signaling has been shown to induce EC glycolysis, and glycolytic activity can in turn upregulate the YAP/TAZ pathway (Enzo et al., 2015; Bertero et al., 2016; Kim J. et al., 2017), which has been hypothesized to result in a cyclical and sustained pro-inflammatory response in the perturbed endothel…”
BackgroundAngiogenesis in the atherosclerotic plaque
Camaré, C., Pucelle, M., Nègre-Salvayre, A., & Salvayre, R. (2017) · Redox Biology · doi:10.1016/j.redox.2017.01.007 · Cited by 401 · cited 1×
“, 2017) and sprouting angiogenesis, the latter of which supports plaque progression through increased supply of oxygen and nutrients (Camaré et al., 2017; Graney et al., 2020).”
BackgroundWinter, P. M., Neubauer, A. M., Caruthers, S. D., Harris, T. D., Robertson, J. D., Williams, T. A., Schmieder, A. H., Hu, G., Allen, J. S., Lacy, E. K., et al. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000235724.11299.76 · Cited by 379 · cited 1×
“fumagillin have likewise been shown to limit neovascularization in mice and demonstrate prolonged activity when combined with statin treatment (Winter et al., 2006; Winter et al., 2008) (Figure 2).”
BackgroundEndothelial permeability, LDL deposition, and cardiovascular risk factors—a review
Mundi, S., Massaro, M., Scoditti, E., Carluccio, M. A., van Hinsbergh, V. W. M., Iruela-Arispe, M. L., & De Caterina, R. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvx226 · Cited by 367
Thorp, E., Cui, D., Schrijvers, D. M., Kuriakose, G., & Tabas, I. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.167197 · Cited by 357
van der Heijden, T., Kritikou, E., Venema, W., van Duijn, J., van Santbrink, P. J., Slütter, B., Foks, A. C., Bot, I., & Kuiper, J. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309575 · Cited by 348 · cited 2×
“…the NLRP3 inflammasome, including the natural compound arglabin (Abderrazak et al., 2015), colchicine (Fernando et al., 2017), and the small molecule inhibitor MCC950 (van der Heijden et al., 2017), have been shown to ameliorate endothelial inflammation and atherosclerosis in preclinical studies.”
BackgroundXiao, H., Lu, M., Lin, T. Y., Chen, Z., Chen, G., Wang, W.-C., Marin, T., Shentu, T.-P., Wen, L., Gongol, B., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002714 · Cited by 257
Sedding, D. G., Boyle, E. C., Demandt, J. A. F., Sluimer, J. C., Dutzmann, J., Haverich, A., & Bauersachs, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00706 · Cited by 228
Disturbed Flow Promotes Endothelial Senescence via a p53-Dependent Pathway
Warboys, C. M., de Luca, A., Amini, N., Luong, L., Duckles, H., Hsiao, S., White, A., Biswas, S., Khamis, R., Chong, C. K., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.303415 · Cited by 227 · cited 1×
“, 2013), and enhanced senescence and turnover in ECs (Xu, 2009; Warboys et al., 2014).”
BackgroundThe guidance receptor plexin D1 is a mechanosensor in endothelial cells
Mehta, V., Pang, K.-L., Rozbesky, D., Nather, K., Keen, A., Lachowski, D., Kong, Y., Karia, D., Ameismeier, M., Huang, J., et al. (2020) · Nature · doi:10.1038/s41586-020-1979-4 · Cited by 221
Cai, B., Kasikara, C., Doran, A. C., Ramakrishnan, R., Birge, R. B., & Tabas, I. (2018) · Science Signaling · doi:10.1126/scisignal.aar3721 · Cited by 175 · cited 1×
“, 2020) or activation of the macrophage cell surface receptor MER proto-oncogene, tyrosine kinase (Thorp et al., 2008; Cai et al., 2018).”
BackgroundWinter, P. M., Caruthers, S. D., Zhang, H., Williams, T. A., Wickline, S. A., & Lanza, G. M. (2008) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2008.06.003 · Cited by 166 · cited 1×
“fumagillin have likewise been shown to limit neovascularization in mice and demonstrate prolonged activity when combined with statin treatment (Winter et al., 2006; Winter et al., 2008) (Figure 2).”
BackgroundVaradharaj, S., Kelly, O. J., Khayat, R. N., Kumar, P. S., Ahmed, N., & Zweier, J. L. (2017) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2017.00064 · Cited by 101
Circulating exosomes in cardiovascular disease: Novel carriers of biological information
Liu, Q., Piao, H., Wang, Y., Zheng, D., & Wang, W. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111148 · Cited by 70
Targeting vasa vasorum dysfunction to prevent atherosclerosis
Boyle, E. C., Sedding, D. G., & Haverich, A. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.08.003 · Cited by 60 · cited 1×
“, 2016), as well as the contribution to pathogenesis and the therapeutic potential of the vasa vasorum in treating atherosclerosis (Xu et al., 2015; Boyle et al., 2017; Sedding et al., 2018), has been previously discussed in detail.”
Background
Cited by
Insulin resistance and cardiovascular disease
Kosmas, C. E., Bousvarou, M. D., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E. (2023) · Journal of International Medical Research · doi:10.1177/03000605231164548 · Cited by 385
Micro- and nanoplastics: A new cardiovascular risk factor?
Zhu, X., Wang, C., Duan, X., Liang, B., Genbo Xu, E., & Huang, Z. (2023) · Environment International · doi:10.1016/j.envint.2022.107662 · Cited by 273
Metadata
- Authors
- Botts, S. R., Fish, J. E., & Howe, K. L.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2021-12-22
- Volume
- 12
- Pages
- 787541-787541
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W4200037999
- Cited by
- 171
- References
- 34
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.